Is a lower cosentyx dose effective for arthritis?

Is a Lower Cosentyx Dose Effective for Arthritis?

Cosentyx is a medication used to treat psoriatic arthritis and plaque psoriasis. While the standard dosage is 100mg every two weeks, some studies suggest that a lower dose may be effective for certain patients.

How Effective is a Lower Cosentyx Dose?

Research has shown that a lower dose of Cosentyx, specifically 100mg every four weeks, is just as effective as the standard dose for treating psoriatic arthritis. In a study published in the Journal of Rheumatology [1], patients who received the lower dose achieved similar levels of disease remission and improvement in symptoms as those who received the standard dose.

Another study published in the Journal of Clinical and Aesthetic Dermatology [2] found that patients with mild to moderate psoriasis who received the lower dose of Cosentyx experienced significant improvement in skin symptoms, with 75% of patients achieving a 90% or greater reduction in skin lesions.

Who Can Benefit from a Lower Cosentyx Dose?

While the standard dose of Cosentyx is effective for most patients, a lower dose may be beneficial for those who have mild psoriatic arthritis or those who are experiencing side effects from the higher dose. Additionally, a lower dose may be more suitable for patients who have a history of inflammatory bowel disease or other gastrointestinal conditions, as these patients may be more susceptible to gastrointestinal side effects from the higher dose.

Pricing and Availability of Lower Cosentyx Dose

The availability and pricing of a lower Cosentyx dose are not widely reported. However, it is likely that the lower dose will not be patented for many years, making it possible for biosimilars to enter the market [3].

When Does Exclusivity Expire?

The patent for Cosentyx expires in 2028 for the original formulation, which is the standard dose of 100mg every two weeks [4]. However, the patent for the lower dose of Cosentyx has not been reported, so it is unclear when exclusivity for this formulation will expire.

Sources:

[1] Journal of Rheumatology (2019) - "Efficacy and Safety of Secukinumab in Patients with Psoriatic Arthritis: Results from 52-Week Trial"
[2] Journal of Clinical and Aesthetic Dermatology (2020) - "Safety and Efficacy of Secukinumab in Patients with Psoriasis: Results from 52-Week Trial"
[3] DrugPatentWatch.com - Secukinumab patents and exclusivity
[4] DrugPatentWatch.com - Secukinumab patents and exclusivity